Home > News > Mission Pharmacal Obtains Observation Rights to Nanobac Life Sciences
August 11th, 2005
Mission Pharmacal Obtains Observation Rights to Nanobac Life Sciences
Abstract:
Nanobac Life Sciences, Inc. announced today that Mission Pharmacal Company, a global pharmaceutical company and leading kidney stone disease reference laboratory, executed an observation rights agreement with Nanobac Life Sciences to observe a multi-center collaboration involving researchers from Nanobac, the University of California, San Francisco (UCSF), and NASA's Johnson Space Center, to study kidney stone formation.
Source:
businesswire
Bookmark:
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||